Home Featured Page 156

Featured

Latest

No Questions Asked: FDA’s Psychedelics Public Hearing

Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder

THE GATEWAY: Live From DC After the FDA Psychedelics Hearing

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Numinus Launches Psychedelic-Assisted Therapy for Chronic and Serious Medical Illness

PT368 – Ketamine, Group Work, and the Power of Just Being...

COMPASS Pathways plc to announce third quarter 2022 financial results on...

HAVN Life Announces Retail Listing With Loblaws Company Ltd.

Mindset Pharma Announces Poster Presentations at Two Upcoming Scientific Conferences

MINDCURE Announces Financial Results for the First Quarter of Fiscal 2023USA...

Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami...

Free Webinar — Psychedelics for Veterans: The Battle for a Better...

Free Webinar — Starting a KAP Practice: Best Practices from Journey...

Free Webinar — Traditional and Modern Perspectives on Healing

EDITOR PICKS

No Questions Asked: FDA’s Psychedelics Public Hearing

Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder

THE GATEWAY: Live From DC After the FDA Psychedelics Hearing

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

No Questions Asked: FDA’s Psychedelics Public Hearing

Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder

THE GATEWAY: Live From DC After the FDA Psychedelics Hearing

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Numinus Launches Psychedelic-Assisted Therapy for Chronic and Serious Medical Illness

PT368 – Ketamine, Group Work, and the Power of Just Being...

COMPASS Pathways plc to announce third quarter 2022 financial results on...

HAVN Life Announces Retail Listing With Loblaws Company Ltd.

Mindset Pharma Announces Poster Presentations at Two Upcoming Scientific Conferences

MINDCURE Announces Financial Results for the First Quarter of Fiscal 2023USA...

Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami...

Free Webinar — Psychedelics for Veterans: The Battle for a Better...

Free Webinar — Starting a KAP Practice: Best Practices from Journey...

Free Webinar — Traditional and Modern Perspectives on Healing

EDITOR PICKS

No Questions Asked: FDA’s Psychedelics Public Hearing

Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder

THE GATEWAY: Live From DC After the FDA Psychedelics Hearing

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY